HMA+DLI vs DLI Preemptive Therapy Based on MRD for AL Undergoing Allo-HSCT

Allogeneic hematopoietic cell transplantation (Allo‐HSCT) is an effective therapy for acute leukemia, but relapse is the most common problem affecting long‐term survivors of allo‐HSCT. Therapy options for relapse include stopping immune suppression, re‐induction of chemotherapy, donor lymphocyte infusion (DLI) or combination therapy. One method of solving relapse is to intervene before hematologic or pathologic relapse occurs based on minimal residual disease (MRD) . DLI is an effective post‐transplantation therapy based on MRD for relapse. Whether combination of hypomethylating agents (HMA) and DLI could improve outcomes remains unclear. In this prospective randomized controlled study, the safety and efficacy of HMA+DLI and DLI preemptive therapy based on minimal residual disease in acute leukemia undergoing allo‐HSCT are evaluated.